CClinicalTrials.gg
WithdrawnNCT00852878Updated Jun 23, 2015

The Treatment of Recurrent Abdominal Pain in Children

An interventional study of Biofeedback and Behavioral Protocol in Recurrent Abdominal Pain, sponsored by Kaiser Permanente. Withdrawn at 1 site in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-06-23.

Sponsored by Kaiser Permanente · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Not enough interested participants
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Study summary

The purpose of this study is to determine if two treatments, a biofeedback and behavioral protocol, for recurrent abdominal pain are equally effective.

Read the detailed description

Recurrent abdominal pain (RAP) is a functional disorder that affects approximately 10 to 25% of children in the United States. This population tends to be heavy medical users in a search of a treatment for the chronic pain, but at this time there is no standard treatment protocol. The literature proposes that there are two effective treatments for RAP, a relaxation protocol by Sanders et al. (1994) and a biofeedback protocol currently in use at Kaiser, but neither treatment has been widely accepted as standard treatment. A purpose of this study is to gather more data on both treatments to help move one or both treatments into the standard of care for RAP. The hypothesis of this study is that the biofeedback and the relaxation protocols will have equivalent treatment outcomes.

02

Conditions studied

  • Recurrent Abdominal Pain

Keywords

  • Recurrent Abdominal Pain
  • Biofeedback
  • Heart Rate Variability
03

In context

Recurrence

4,279 studies on the registry are indexed under Recurrence; 988 are open to participants now.

Browse Recurrence studies →

Lead sponsor

Kaiser Permanente is the lead sponsor of 385 studies on the registry; 41 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • who speak English
  • diagnosis with Recurrent abdominal pain

Exclusion criteria

Exclusion Criteria:

  • lactose intolerance, urinary tract infections, or recent head trauma;
  • the use of prescribed or over he counter medications, which may interfere with the biofeedback data;
  • currently receiving other treatment for recurrent abdominal pain;
  • the receipt of a recent and related surgical procedure;
  • children who met criteria for depression or anxiety disorder
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Biofeedback

    heart rate variability biofeedback

    Behavioral: Biofeedback

  • Active comparator
    Behavioral

    Behavioral intervention will provide parent and child with a variety of pain management techniques such as relaxation, distraction, contingency management, and coping statements

    Behavioral: Behavioral Protocol

Interventions

  • BehavioralBiofeedback

    Biofeedback will teach resonant frequency breathing for 6-8 sessions

    Also known as: resonant frequency breathing

  • BehavioralBehavioral Protocol

    Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions

    Also known as: relaxation, distraction, and coping statements

06

What researchers measure

Primary outcomes

  1. The measurable primary outcome will use equivalency testing on changes in pain diary ratings, using the average weekly pain intensity and frequency as recorded in the pain dairy

    Time frame: 3 Months

Secondary outcomes

  1. A measurable secondary outcome will be changes in heart rate variability

    Time frame: 3 Months

07

Study locations

1 site
  • Kaiser Permanente Vandever Medical Offices
    San Diego, California 92120, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00852878
Lead sponsor
Kaiser Permanente
Responsible party
Sponsor
First posted
Feb 27, 2009
Start date
Mar 2009
Primary completion
Jan 2010 (estimated)
Last update
Jun 23, 2015

Study contacts

Warren L Shapiro, MD
principal investigator · Kaiser Permanente

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion